MONMOUTH JUNCTION, N.J.,
Jan. 20, 2017 /PRNewswire/ -- CytoSorbents Corporation
(NASDAQ: CTSO), a critical care immunotherapy leader using blood
purification to treat deadly inflammation in critically-ill and
cardiac surgery patients around the world, announces the marketing
launch and commercial availability of the VetResQ™ sorbent
cartridge for the United States
veterinary market. VetResQ is a broad spectrum blood purification
adsorber designed to help treat deadly inflammation and toxic
injury in animals with critical illnesses such as septic shock,
toxic shock syndrome, severe systemic inflammation, toxin-mediated
diseases, pancreatitis, trauma, liver failure, and drug
intoxication.
VetResQ is being showcased at the American College of Veterinary
Emergency and Critical Care (ACVECC) Post-Graduate Review Course on
January 20-21, 2017 in Honolulu, Hawaii, where CytoSorbents is one of
the main sponsors and will have a prominent booth position to talk
to interested parties. The ACVECC conference is held in conjunction
with the 46th Society of Critical Care Medicine Congress
(January 21-25, 2017), where
CytoSorbents is also an exhibitor (Booth #606).
Mr. Vincent Capponi, Chief
Operating Officer of CytoSorbents stated, "The VetResQ adsorber
provides a new and unique treatment for severe inflammation,
toxin-mediated disease, and drug intoxication not previously
available in the animal health market. VetResQ leverages a similar
underlying blood purification technology in our commercialized
CytoSorb® device that is approved in the European Union and has
been used in more than 20,000 human treatments safely. Whether it
is the sick thoroughbred racehorse or foal suffering from sepsis or
toxic shock syndrome, a dog with acute pancreatitis in terrible
pain, a cat after being struck by a car, or a dog poisoned from
accidentally eating his owner's pill bottles, the pathophysiology
is remarkably similar to what is seen in humans, with a similar
lack of available effective therapies. Our target customers are the
large academic veterinary hospitals and veterinary practices where
services like dialysis are administered. Although this is a
specialized niche market, we are providing this product at the
request of many animal care providers and pet owners, with the goal
of improving clinical outcomes for our most trusted and loved
animal companions."
VetResQ is capable of reducing a broad range of excessive
inflammatory mediators and toxins that could otherwise cause direct
tissue injury or serious systemic inflammation that can rapidly
lead to instability, organ failure, and death. Some of the relevant
substances VetResQ has been shown to remove include:
- Excessive pro- and anti-inflammatory cytokines (Sepsis and SIRS
- systemic inflammatory response syndrome)
- Bacterial toxins such as Toxic shock syndrome toxin, Staph.
aureus alpha-hemolysin, and fungal mycotoxins such as aflatoxin
(Sepsis, infection)
- Pancreatic enzymes (Severe acute pancreatitis)
- Bilirubin (Liver failure)
- Myoglobin (Trauma)
- Activated complement (Autoimmune diseases)
- Lipophilic drugs (Accidental drug intoxication)
VetResQ is manufactured in the United
States by CytoSorbents Corporation in three different sized
cartridges (30mL, 100mL, and 300mL) for the treatment of cats,
dogs, horses and animals of comparable size. VetResQ is compatible
with standard hemodialysis, continuous renal replacement therapy
(CRRT), and hemoperfusion blood pumps. VetResQ is available
only for veterinary animal usage and is not for human use.
For more information, please visit
www.cytosorbents.com/products/VetResQ. For pricing and to order,
please contact Lea Garcia at
lgarcia@cytosorbents.com
About CytoSorbents Corporation (NASDAQ:
CTSO)
CytoSorbents Corporation is a leader in critical care
immunotherapy, specializing in blood purification. Its flagship
product, CytoSorb® is approved in the European Union with
distribution in 42 countries around the world, as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the
"cytokine storm" or "cytokine release syndrome" that could
otherwise cause massive inflammation, organ failure and death in
common critical illnesses such as sepsis, burn injury, trauma, lung
injury and pancreatitis, as well as in cancer immunotherapy. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorb® is also being used during and
after cardiac surgery to remove inflammatory mediators, such as
cytokines and free hemoglobin, which can lead to post-operative
complications, including multiple organ failure. CytoSorbents has
completed its REFRESH (REduction in FREe Hemoglobin) 1 trial - a
multi-center, randomized controlled study that has demonstrated the
safety of intra-operative CytoSorb® use in a heart-lung machine
during complex cardiac surgery. In 2017, the company plans to
initiate a pivotal REFRESH 2 trial intended to support U.S. FDA
approval. CytoSorb® has been used safely in more than 20,000
human treatments to date.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding in excess of $18 million from DARPA, the U.S. Army, the U.S.
Department of Health and Human Services, the National Institutes of
Health (NIH), National Heart, Lung, and Blood Institute (NHLBI),
U.S. Special Operations Command (SOCOM) and others. The Company has
numerous products under development based upon this unique blood
purification technology, protected by 31 issued U.S. patents and
multiple applications pending, including CytoSorb-XL, HemoDefend™,
VetResQ™, ContrastSorb, DrugSorb, and others. For more
information, please visit the Company's websites at
www.cytosorbents.com and www.cytosorb.com or follow us
on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 9, 2016, as updated by the risks reported in
our Quarterly Reports on Form 10-Q, and in the press releases and
other communications to shareholders issued by us from time to time
which attempt to advise interested parties of the risks and factors
which may affect our business. We caution you not to place undue
reliance upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow Us
on Facebook and Twitter
CytoSorbents
Contact: Amy Vogel
Investor
Relations
(732)
398-5394
avogel@cytosorbents.com
|
Public Relations
Contact:
Amy
Phillips
Pascale Communications
412-327-9499
amy@pascalecommunications.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-launches-vetresq-for-us-veterinary-market-300394165.html
SOURCE CytoSorbents Corporation